Xenon xe-129 hyperpolarized - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for xenon xe-129 hyperpolarized and what is the scope of freedom to operate?
Xenon xe-129 hyperpolarized
is the generic ingredient in one branded drug marketed by Polarean and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Xenon xe-129 hyperpolarized has six patent family members in six countries.
One supplier is listed for this compound.
Summary for xenon xe-129 hyperpolarized
| International Patents: | 6 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 99 |
| DailyMed Link: | xenon xe-129 hyperpolarized at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for xenon xe-129 hyperpolarized
Generic Entry Date for xenon xe-129 hyperpolarized*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
GAS;INHALATION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for xenon xe-129 hyperpolarized
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| U.S. Army Medical Research Acquisition Activity | Early Phase 1 |
| National Science and Technology Council | Phase 2 |
| Robert Flavell, MD, PhD | Early Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for xenon xe-129 hyperpolarized
US Patents and Regulatory Information for xenon xe-129 hyperpolarized
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Polarean | XENOVIEW | xenon xe-129 hyperpolarized | GAS;INHALATION | 214375-001 | Dec 23, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Polarean | XENOVIEW | xenon xe-129 hyperpolarized | GAS;INHALATION | 214375-001 | Dec 23, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Polarean | XENOVIEW | xenon xe-129 hyperpolarized | GAS;INHALATION | 214375-001 | Dec 23, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for xenon xe-129 hyperpolarized
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hungary | E045999 | ⤷ Try a Trial | |
| World Intellectual Property Organization (WIPO) | 2015127208 | ⤷ Try a Trial | |
| Australia | 2015218883 | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
